Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease

INTRODUCTION: Solanezumab is a humanized monoclonal antibody that preferentially binds to soluble amyloid β and promotes its clearance from the brain in preclinical studies. The objective of this study was to assess the effect of solanezumab in slowing global and anatomically localized brain atrophy...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Alzheimers Dement (N Y)
Egile Nagusiak: Schwarz, Adam J., Sundell, Karen L., Charil, Arnaud, Case, Michael G., Jaeger, Ralf K., Scott, David, Bracoud, Luc, Oh, Joonmi, Suhy, Joyce, Pontecorvo, Michael J., Dickerson, Bradford C., Siemers, Eric R.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier 2019
Gaiak:
Featured Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6675941/
https://ncbi.nlm.nih.gov/pubmed/31388559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trci.2019.05.007
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak